## Table 20

## In this guide

## In this guide

- 1. Table 3 Annex A
- 2. Table 4 Annex A
- 3. Table 5 Annex A
- 4. Table 6 Annex A
- 5. Table 7 Annex A
- 6. Table 8 Annex A
- 7. Table 9 Annex A
- 8. Table 10 Annex A
- 9. Table 11 Annex A
- 10. Table 12 Annex A
- 11. Table 13 Annex A
- 12. Table 14 Annex A
- 13. Table 15 Annex A
- 14. Table 16 Annex A
- 15. Table 17 Annex A
- 16. Table 18 Annex A
- 17. Table 19 Annex A
- 18. Table 20 Annex A
- 19. Table 21 Annex A

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

## Table 20. Developmental toxicity studies for PFCAs - PFBA

\*Derived by contractor; \*\* calculated according to EFSA. (2012); NR – not reported; NA – not applicable.

Substance / CAS no. / purity / reference	Strain & species / sex / no. of animals	Dose (mg/kg bw/day) / vehicle / route of admin / duration / Guideline (GL) study / Good Laboratory Practice (GLP) status	)	Observed effects at LOAEL ( controls vs treated groups)  Recovery (controls vs treated groups)	Published NOAEL / LOAEL (mg/kg bw/day)	Study author comments
---	---	--	---	--	--	-----------------------------

		0, 35, 175		Maternal		
		or 350,	At 35 mg/kg	effects		Findings reflect a
		Water,	bw/day (mean ± SE)	↑ liver weight		general hepatic
		Gavage,	Serum: 3.78 ±	(data only reported in	Maternal:	response to
PFBA ammonium salt	Pregnant CD-1 mice.	GD1-GD17,	1.01	figures).	35 / 175*	PFBA in the mouse and
		Non-GL study,	Liver: 1.41 ± 0.42.	Recovery:	Recovery:	also indicate indirectly an
CAS No. not	Female	GLP not	At 175 mg/kg	Maternal effects	Maternal:	effective transplacental
given	5/dose.	stated.	bw/day		35 / 175*	transfer of
98%.	_	Recovery	Serum: 4.44 ±	Liver weight		the chemical from the
Das et al.	group:	group:	0.65	comparable		maternal
(2008)	5/dose.	0, 35, 175 or 350,	Liver: 1.60 ± 0.25.	to controls after 3		compartment to the
		GD1-GD18,	0.23.	weeks (data NR).		foetuses,
		PND22.		,		leading to similar liver enlargement.